Cwm LLC acquired a new stake in Blueprint Medicines Co. (NASDAQ:BPMC – Get Rating) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 320 shares of the biotechnology company’s stock, valued at approximately $34,000.
Several other large investors have also recently bought and sold shares of BPMC. Morgan Stanley boosted its stake in shares of Blueprint Medicines by 763.6% in the 2nd quarter. Morgan Stanley now owns 535,446 shares of the biotechnology company’s stock valued at $47,098,000 after purchasing an additional 473,445 shares during the last quarter. State of New Jersey Common Pension Fund D boosted its stake in shares of Blueprint Medicines by 4.2% in the 3rd quarter. State of New Jersey Common Pension Fund D now owns 34,956 shares of the biotechnology company’s stock valued at $3,594,000 after purchasing an additional 1,415 shares during the last quarter. Nordea Investment Management AB bought a new stake in shares of Blueprint Medicines in the 3rd quarter valued at $7,382,000. SG Americas Securities LLC boosted its stake in shares of Blueprint Medicines by 20.0% in the 3rd quarter. SG Americas Securities LLC now owns 24,175 shares of the biotechnology company’s stock valued at $2,485,000 after purchasing an additional 4,029 shares during the last quarter. Finally, Benjamin F. Edwards & Company Inc. bought a new stake in shares of Blueprint Medicines in the 3rd quarter valued at $78,000.
NASDAQ BPMC opened at $63.52 on Friday. Blueprint Medicines Co. has a 1 year low of $53.26 and a 1 year high of $117.86. The firm has a market cap of $3.76 billion, a price-to-earnings ratio of -5.80 and a beta of 0.95. The company has a fifty day moving average price of $64.86 and a 200-day moving average price of $85.67.
A number of research firms recently issued reports on BPMC. Zacks Investment Research upgraded shares of Blueprint Medicines from a “sell” rating to a “hold” rating and set a $68.00 target price on the stock in a research report on Monday, March 28th. Guggenheim boosted their target price on shares of Blueprint Medicines from $120.00 to $122.00 in a research report on Monday, January 3rd. Wedbush reiterated an “outperform” rating and set a $126.00 target price on shares of Blueprint Medicines in a research report on Monday, February 28th. StockNews.com initiated coverage on shares of Blueprint Medicines in a report on Thursday, March 31st. They set a “sell” rating on the stock. Finally, SVB Leerink lowered their price objective on shares of Blueprint Medicines from $93.00 to $82.00 and set a “market perform” rating on the stock in a report on Thursday, February 17th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $106.45.
In other Blueprint Medicines news, CEO Jeffrey W. Albers sold 5,000 shares of the stock in a transaction dated Wednesday, April 6th. The shares were sold at an average price of $70.11, for a total transaction of $350,550.00. Following the completion of the transaction, the chief executive officer now owns 183,243 shares in the company, valued at $12,847,166.73. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Ariel Hurley sold 2,339 shares of the stock in a transaction dated Thursday, March 10th. The stock was sold at an average price of $57.15, for a total transaction of $133,673.85. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 10,575 shares of company stock valued at $677,614. 3.34% of the stock is owned by company insiders.
Blueprint Medicines Company Profile (Get Rating)
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma.
- Get a free copy of the StockNews.com research report on Blueprint Medicines (BPMC)
- 3 Resilient Stocks to Buy for Retirement
- MarketBeat: Week in Review 4/18 – 4/22
- Tractor Supply Company Reaps What It Sows
- Snap (NYSE: SNAP) Gives Investors A Mixed Bag
- MarketBeat Podcast: 3 Stocks Flashing Buy Signals
Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.